Tekmira Pharmaceuticals Corporation Share Price Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Sales 2024 * | 9.04M 6.64M 553M | Sales 2025 * | 8.08M 5.93M 494M | Capitalization | 765M 562M 46.8B |
---|---|---|---|---|---|
Net income 2024 * | -98M -71.95M -5.99B | Net income 2025 * | -102M -74.89M -6.24B | EV / Sales 2024 * | 84.7 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 94.7 x |
P/E ratio 2024 * |
-7.59
x | P/E ratio 2025 * |
-7.55
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.71% |
Latest transcript on Tekmira Pharmaceuticals Corporation
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 01/14/01 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 11/18/11 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 01/14/01 | |
James Meyers
BRD | Director/Board Member | 59 | 23/18/23 |
Daniel Burgess
BRD | Director/Board Member | 62 | 23/17/23 |
1st Jan change | Capi. | |
---|---|---|
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B | |
-6.32% | 8.35B |